Overview

A Phase 2 Extension of Study GCS-100-CS-4003

Status:
Withdrawn
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the safety and tolerability of extended dosing with a fixed dose of GCS-100 3 mg IV push in patients with Chronic Kidney Disease (CKD).
Phase:
Phase 2
Details
Lead Sponsor:
La Jolla Pharmaceutical Company